Aspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aspira Women's Health (Nasdaq: AWH), a bio-analytical women's health company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel. CEO Nicole Sandford will deliver a presentation, available on-demand from September 9 at 7:00 am ET for registered attendees.
Company management will be available for in-person one-on-one meetings on September 10 and 11. Interested investors should contact H.C. Wainwright representatives. A replay of the presentation will be posted on the Events page of Aspira's Investors section on their website when available.
Aspira Women's Health (Nasdaq: AWH), un'azienda bio-analitica nel settore della salute femminile, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annua di Investimenti H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024 presso il Lotte New York Palace Hotel. L'amministratore delegato Nicole Sandford terrà una presentazione, disponibile on-demand dal 9 settembre alle 7:00 ET per i partecipanti registrati.
Il management dell'azienda sarà disponibile per incontri faccia a faccia individuali il 10 e 11 settembre. Gli investitori interessati possono contattare i rappresentanti di H.C. Wainwright. Una registrazione della presentazione verrà pubblicata nella pagina Eventi nella sezione Investitori del sito web di Aspira non appena sarà disponibile.
Aspira Women's Health (Nasdaq: AWH), una empresa bioanalítica de salud femenina, anunció su participación en la 26ª Conferencia Anual de Inversiones Globales de H.C. Wainwright. El evento se llevará a cabo del 9 al 11 de septiembre de 2024 en el Lotte New York Palace Hotel. La CEO Nicole Sandford realizará una presentación, disponible bajo demanda a partir del 9 de septiembre a las 7:00 am ET para los asistentes registrados.
La dirección de la empresa estará disponible para reuniones individuales en persona los días 10 y 11 de septiembre. Los inversores interesados deben contactar a los representantes de H.C. Wainwright. Una repetición de la presentación se publicará en la página de Eventos de la sección de Inversores del sitio web de Aspira cuando esté disponible.
Aspira Women's Health (Nasdaq: AWH), 여성 건강 분야의 바이오 분석 회사, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 Lotte New York Palace Hotel에서 열릴 예정입니다. CEO Nicole Sandford는 발표를 진행하며, 등록한 참석자는 9월 9일 오전 7시 ET부터 주문형으로 이용할 수 있습니다.
회사 경영진은 9월 10일과 11일에 대면 일대일 회의를 위해 참석할 예정입니다. 관심 있는 투자자는 H.C. Wainwright 대표에게 연락해야 합니다. 발표의 재생은 Aspira 웹사이트 투자자 섹션의 이벤트 페이지에 공지가 올라오면 게시될 예정입니다.
Aspira Women's Health (Nasdaq: AWH), une entreprise bio-analytiques spécialisée dans la santé des femmes, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright. Cet événement se déroulera du 9 au 11 septembre 2024 à l'Hôtel Lotte New York Palace. La PDG Nicole Sandford fera une présentation, disponible en demande à partir du 9 septembre à 7h00 ET pour les participants inscrits.
La direction de l'entreprise sera disponible pour des rencontres individuelles en personne les 10 et 11 septembre. Les investisseurs intéressés doivent contacter les représentants de H.C. Wainwright. Un enregistrement de la présentation sera publié sur la page Événements de la section Investisseurs du site web d'Aspira dès qu'il sera disponible.
Aspira Women's Health (Nasdaq: AWH), ein bioanalytisches Unternehmen im Bereich Frauengesundheit, gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt. Die Veranstaltung findet vom 9. bis 11. September 2024 im Lotte New York Palace Hotel statt. CEO Nicole Sandford wird eine Präsentation halten, die für registrierte Teilnehmer ab 9. September um 7:00 Uhr ET on-demand verfügbar sein wird.
Das Unternehmensmanagement wird am 10. und 11. September für persönliche Einzelgespräche zur Verfügung stehen. Interessierte Investoren sollten die Vertreter von H.C. Wainwright kontaktieren. Eine Wiederholung der Präsentation wird auf der Events-Seite im Investorenbereich der Webseite von Aspira veröffentlicht, sobald sie verfügbar ist.
- None.
- None.
AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women’s Health will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.
The presentation will be available on demand on Monday, September 9 at 7:00 am ET for those registered to attend the conference. Company management will be available for in person one-on-one meetings on Tuesday, September 10 and Wednesday, September 11, 2024. Interested investors should contact their representative at H.C. Wainwright.
A replay of the presentation will be posted, when available, on the Events page of the Investors section of the Aspira website.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDx risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDx test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.
Investor Relations Contact:
Nicole Sandford
Chief Executive Officer
Investors@aspirawh.com
FAQ
When is Aspira Women's Health (AWH) presenting at the H.C. Wainwright conference?
Where is the H.C. Wainwright Global Investment Conference being held in 2024?
Will Aspira Women's Health (AWH) be available for one-on-one meetings at the conference?
How can investors access the replay of Aspira Women's Health (AWH) presentation?
